Peter Higgins

26.3k total citations · 8 hit papers
331 papers, 15.5k citations indexed

About

Peter Higgins is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Peter Higgins has authored 331 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 202 papers in Genetics, 162 papers in Epidemiology and 107 papers in Surgery. Recurrent topics in Peter Higgins's work include Inflammatory Bowel Disease (196 papers), Microscopic Colitis (126 papers) and Helicobacter pylori-related gastroenterology studies (29 papers). Peter Higgins is often cited by papers focused on Inflammatory Bowel Disease (196 papers), Microscopic Colitis (126 papers) and Helicobacter pylori-related gastroenterology studies (29 papers). Peter Higgins collaborates with scholars based in United States, United Kingdom and Canada. Peter Higgins's co-authors include Akbar K. Waljee, Ryan W. Stidham, Amit G. Singal, Stephen B. Gruber, Laura A. Johnson, Maneesh Dave, Shail M. Govani, Marie‐France Demierre, Ernest T. Hawk and Scott M. Lippman and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Peter Higgins

317 papers receiving 15.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

2012 1.2k citations Wolfgang Hueber, Bruce E. Sands et al. Gut profile →
Statins and cancer prevention

2005 647 citations Peter Higgins et al. profile →
Statins and the Risk of Colorectal Cancer

2005 612 citations Peter Higgins et al. profile →
A Primer on Effectiveness and Efficacy Trials

2014 441 citations Peter Higgins, Akbar K. Waljee et al. profile →
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

2017 296 citations Stefan Schreiber, Bruce E. Sands et al. Gut profile →
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

2015 284 citations Peter Higgins et al. profile →
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

2020 207 citations Stefan Schreiber, Wen Zhou et al. profile →
Management of Crohn Disease

2021 197 citations Kelly C. Cushing, Peter Higgins profile →

Peers

Countries citing papers authored by Peter Higgins

Since Specialization

Citations

This map shows the geographic impact of Peter Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Higgins more than expected).

Fields of papers citing papers by Peter Higgins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Higgins. The network helps show where Peter Higgins may publish in the future.

Co-authorship network of co-authors of Peter Higgins

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Higgins. A scholar is included among the top collaborators of Peter Higgins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Higgins. Peter Higgins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disseminated Chickenpox Following Live Varicella Vaccination in a Crohn’s Disease Patient on Combination Immunosuppression 2025 ·Case Reports in Gastrointestinal Medicine ·(unknown), (unknown), Peter Higgins, Jeffrey Berinstein	0
2	AOUSDOHtools: An R Package for Social Determinants of Health Survey data in the All of Us Research Program 2025 ·The Journal of Open Source Software ·(unknown), Theresa A. Koleck, Chen Zhang, Peter Higgins, Caitlin Dreisbach	0
3	A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch 2025 ·The American Journal of Gastroenterology ·Edward L. Barnes, Laura E. Raffals, Taha Qazi, Parakkal Deepak, Sam S. Chang, Poonam Beniwal‐Patel, Peter Higgins, Raymond K. Cross, (unknown), Chelsea Anderson, Millie D. Long, Hans Herfarth, Marla C. Dubinsky, Michael D. Kappelman, Maia Kayal	0
4	Reddit as a Social Media Self-Management Tool for Inflammatory Bowel Disease: Qualitative Analysis 2025 ·Journal of Medical Internet Research ·(unknown), (unknown), (unknown), Jeffrey Berinstein, Kira L. Newman, Sarah T. Hawley, Minal Patel, Peter Higgins, Ken Resnicow, Sarah L. Krein, Shirley Cohen‐Mekelburg	1
5	Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies 2024 ·Crohn s & Colitis 360 ·Millie D. Long, Stefan Schreiber, Toshifumi Hibi∥, Theresa Hunter, Deborah A. Fisher, (unknown), Richard Moses, Peter Higgins, James O. Lindsay, Scott D. Lee, Rodrigo Escobar, Vipul Jairath	4
6	Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch 2024 ·Inflammatory Bowel Diseases ·Maia Kayal, Elizabeth A. Spencer, Matthew D. Smyth, Laura E. Raffals, Taha Qazi, Parakkal Deepak, Poonam Beniwal‐Patel, (unknown), Peter Higgins, (unknown), Chelsea Anderson, Millie D. Long, Hans Herfarth, Marla C. Dubinsky, Edward L. Barnes	1
7	The Microbiome in Quiescent Crohn’s Disease With Persistent Symptoms Show Disruptions in Microbial Sulfur and Tryptophan Pathways 2023 ·SHILAP Revista de lepidopterología ·Jonathan L. Golob, Krishna Rao, Jeffrey Berinstein, William D. Chey, Chung Owyang, Nobuhiko Kamada, Peter Higgins, Vincent B. Young, Shrinivas Bishu, Allen Lee	2
8	Profiles of Web-based Portal Users with Inflammatory Bowel Disease 2023 ·Inflammatory Bowel Diseases ·Mohamed Noureldin, Kira L. Newman, Peter Higgins, John D. Piette, Ken Resnicow, Jeremy Louissaint, Brooke Kenney, Jeffrey Berinstein, Akbar K. Waljee, (unknown), Shirley Cohen‐Mekelburg	1
9	Risk Variants in or NearZBTB40ANDNFATC1Increase the Risk of Both IBD and Adverse Bone Health Outcomes Highlighting Common Genetic Underpinnings Across Both Diseases 2023 ·Inflammatory Bowel Diseases ·Kelly C. Cushing, Yanhua Chen, Xiaomeng Du, Vincent Chen, Annapurna Kuppa, Peter Higgins, Elizabeth K. Speliotes	2
10	Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the Pouch 2023 ·The American Journal of Gastroenterology ·Maia Kayal, Parakkal Deepak, Poonam Beniwal‐Patel, Laura E. Raffals, Marla C. Dubinsky, Sam S. Chang, Peter Higgins, Yue Jiang, Raymond K. Cross, Millie D. Long, Hans Herfarth, Edward L. Barnes	4
11	Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective Cohort 2023 ·Crohn s & Colitis 360 ·Edward L. Barnes, Poonam Beniwal‐Patel, Parakkal Deepak, Laura H. Raffals, Maia Kayal, Marla C. Dubinsky, (unknown), Peter Higgins, (unknown), Chelsea Anderson, Raymond K. Cross, Millie D. Long, Hans Herfarth	1
12	An Assessment of Comparative Medication Durability in Inflammatory Bowel Disease Patients With and Without Co-morbid Psoriasis, Rheumatoid Arthritis, and/or Enteropathic Arthritis 2023 ·Digestive Diseases and Sciences ·Kelly C. Cushing, Jóhann E. Guðjónsson, Elizabeth K. Speliotes, Peter Higgins	1
13	Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis 2023 ·Crohn s & Colitis 360 ·Remo Panaccione, Eric B. Collins, Gil Melmed, Séverine Vermeire, Silvio Danese, Peter Higgins, C.S. Kwon, Wen Zhou, Dapo Ilo, (unknown), Yuri Sánchez González, (unknown)	37
14	The Role of Upadacitinib on the Treatment of Ulcerative Colitis 2023 ·Immunotherapy ·(unknown), Peter Higgins	5
15	Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry 2022 ·Crohn s & Colitis 360 ·Edward L. Barnes, Parakkal Deepak, Poonam Beniwal‐Patel, Laura H. Raffals, Maia Kayal, Marla C. Dubinsky, Sam S. Chang, Peter Higgins, (unknown), Joseph A. Galanko, Yue Jiang, Raymond K. Cross, Millie D. Long, Hans Herfarth	9
16	Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn’s Disease: A Systematic Review 2021 ·Clinical Gastroenterology and Hepatology ·Calen A. Steiner, Jeffrey Berinstein, Jeremy Louissaint, Peter Higgins, Jason R. Spence, Carol Shannon, Cathy Lu, Ryan W. Stidham, Joel G. Fletcher, David H. Bruining, Brian G. Feagan, Vipul Jairath, Mark E. Baker, Dominik Bettenworth, Florian Rieder	40
17	Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota 2020 ·Nature Medicine ·Hiroko Nagao‐Kitamoto, Jhansi L. Leslie, Sho Kitamoto, Chunsheng Jin, Kristina A. Thomsson, Merritt Gillilland, Peter Kuffa, Yoshiyuki Goto, Robert R. Jenq, Chiharu Ishii, Akiyoshi Hirayama, Anna M. Seekatz, Eric C. Martens, Kathryn A. Eaton, John Y. Kao, Shinji Fukuda, Peter Higgins, Niclas G. Karlsson, Vincent B. Young, Nobuhiko Kamada	164
18	Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts. 2018 ·PubMed ·Shail M. Govani, (unknown), Mohamed Noureldin, Wyndy L. Wiitala, Peter Higgins, Sameer D. Saini, Jacqueline A. Pugh, Dawn I. Velligan, Ryan W. Stidham, Akbar K. Waljee	6
19	Noninvasive Cardiac Event Monitoring to Detect Atrial Fibrillation After Ischemic Stroke 2013 ·Stroke ·Peter Higgins, Peter W. Macfarlane, Jesse Dawson, Gordon T. McInnes, Peter Langhorne, Kennedy R. Lees	84
20	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial breakdown → 2012 ·Gut ·Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter Higgins, Jan Wehkamp, Brian G. Feagan, Michael Yao, Marek Karczewski, Jacek Karczewski, Nicole Pezous, Stephan Bek, Gerard Bruin, (unknown), C Berger, Marco Londei, Arthur P. Bertolino, Gervais Tougas, Simon Travis, (unknown)	1156

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact